Vir Biotechnology Inc

NASDAQ:VIRUnited States

Yesterday

Show headlines and story abstract

• DJ U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ, from 1 hour ago by Dow Jones

  1 hour ago by Dow Jones
  Companies Mentioned: VIR, AZN, KYMR
  
  By Jared S. Hopkins and Clarence Leong
  
  U.S. drugmakers and biotechs have come to rely on Chinese partners for manufacturing, research and ingredients. Now, some of them are looking for alternatives as geopolitical tensions rise.
  

• -- Earnings Flash (VIR) VIR BIOTECHNOLOGY Posts Q3 Revenue $2.4M, from 8 hours ago by MT Newswires

  8 hours ago by MT Newswires
  Companies Mentioned: VIR
  04:05 PM EDT, 10/31/2024 (MT Newswires) -- ...

• Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 8 hours ago by Dow Jones

  8 hours ago by Dow Jones
  Companies Mentioned: VIR
  
  PRO-XTEN(TM) is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
  VIR BIOTECHNOLOGY, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (unaudited) September 30, December 31, 2024 2023 ---------------- ----------------- ASSETS CURRENT ASSETS: Cash and cash equivalents $ 168,350 $ 241,576 Short-term investments 740,607 1,270,980 Restricted cash and cash equivalents, current 89,598 13,268 Equity investments 5,517 9,853 Prepaid expenses and other current assets 43,085 52,549 ----------- ---------- Total current assets 1,047,157 1,588,226 Intangible assets, net 19,258 22,565 Goodwill 16,938 16,937 Property and equipment, net 64,791 96,018 Operating lease right-of-use assets 60,779 71,182 Restricted cash and cash equivalents, noncurrent 6,382 6,448 Long-term investments 271,495 105,275 Other assets 11,556 12,409 ----------- ---------- TOTAL ASSETS $ 1,498,356 $ 1,919,060 =========== ========== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 7,305 $ 6,334 Accrued and other liabilities 94,658 104,220 Deferred revenue, current 15,198 64,853 ----------- ---------- Total current liabilities 117,161 175,407 Operating lease liabilities, noncurrent 93,405 111,673 Contingent consideration, noncurrent 33,170 25,960 Other long-term liabilities 13,893 15,784 ----------- ---------- TOTAL LIABILITIES 257,629 328,824 ----------- ---------- Commitments and contingencies (Note 8) STOCKHOLDERS' EQUITY: Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2024 and December 31, 2023; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 -- -- Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 136,706,350 and 134,781,286 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 14 13 Additional paid-in capital 1,894,781 1,828,862 Accumulated other comprehensive gain (loss) 1,127 (815) Accumulated deficit (655,195) (237,824) ----------- ---------- TOTAL STOCKHOLDERS' EQUITY 1,240,727 1,590,236 ----------- ---------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 1,498,356 $ 1,919,060 =========== ========== VIR BIOTECHNOLOGY, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended September 30, ------------------------------ 2024 2023 ----------- ----------- Revenues: Collaboration revenue $ (1,102) $ (4,387) Contract revenue 1,391 289 Grant revenue 2,091 6,737 ----------- ----------- Total revenues 2,380 2,639 Operating expenses: Cost of revenue 50 38 Research and development 195,178 145,028 Selling, general and administrative 25,744 40,933 Restructuring, long-lived assets impairment and related charges 12,712 3,372 ----------- ----------- Total operating expenses 233,684 189,371 ----------- ----------- Loss from operations (231,304) (186,732) Other income: Change in fair value of equity investments 1,130 (2,707) Interest income 17,527 21,931 Other (expense) income, net (893) 882 ----------- ----------- Total other income 17,764 20,106 ----------- ----------- Loss before (provision for) benefit from income taxes (213,540) (166,626) (Provision for) benefit from income taxes (177) 3,213 ----------- ----------- Net loss (213,717) (163,413) Net loss attributable to noncontrolling interest -- -- ----------- ----------- Net loss attributable to Vir $ (213,717) $ (163,413) =========== =========== Net loss per share attributable to Vir, basic and diluted $ (1.56) $ (1.22) =========== =========== Weighted-average shares outstanding, basic and diluted 136,653,753 134,289,620 =========== ===========
  

• *DJ Vir Biotechnology 3Q Loss/Shr $1.56 >VIR, from 8 hours ago by Dow Jones

  8 hours ago by Dow Jones
  Companies Mentioned: VIR
  
  PRO-XTEN(TM) is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
  VIR BIOTECHNOLOGY, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (unaudited) September 30, December 31, 2024 2023 ---------------- ----------------- ASSETS CURRENT ASSETS: Cash and cash equivalents $ 168,350 $ 241,576 Short-term investments 740,607 1,270,980 Restricted cash and cash equivalents, current 89,598 13,268 Equity investments 5,517 9,853 Prepaid expenses and other current assets 43,085 52,549 ----------- ---------- Total current assets 1,047,157 1,588,226 Intangible assets, net 19,258 22,565 Goodwill 16,938 16,937 Property and equipment, net 64,791 96,018 Operating lease right-of-use assets 60,779 71,182 Restricted cash and cash equivalents, noncurrent 6,382 6,448 Long-term investments 271,495 105,275 Other assets 11,556 12,409 ----------- ---------- TOTAL ASSETS $ 1,498,356 $ 1,919,060 =========== ========== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 7,305 $ 6,334 Accrued and other liabilities 94,658 104,220 Deferred revenue, current 15,198 64,853 ----------- ---------- Total current liabilities 117,161 175,407 Operating lease liabilities, noncurrent 93,405 111,673 Contingent consideration, noncurrent 33,170 25,960 Other long-term liabilities 13,893 15,784 ----------- ---------- TOTAL LIABILITIES 257,629 328,824 ----------- ---------- Commitments and contingencies (Note 8) STOCKHOLDERS' EQUITY: Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2024 and December 31, 2023; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 -- -- Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 136,706,350 and 134,781,286 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 14 13 Additional paid-in capital 1,894,781 1,828,862 Accumulated other comprehensive gain (loss) 1,127 (815) Accumulated deficit (655,195) (237,824) ----------- ---------- TOTAL STOCKHOLDERS' EQUITY 1,240,727 1,590,236 ----------- ---------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 1,498,356 $ 1,919,060 =========== ========== VIR BIOTECHNOLOGY, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended September 30, ------------------------------ 2024 2023 ----------- ----------- Revenues: Collaboration revenue $ (1,102) $ (4,387) Contract revenue 1,391 289 Grant revenue 2,091 6,737 ----------- ----------- Total revenues 2,380 2,639 Operating expenses: Cost of revenue 50 38 Research and development 195,178 145,028 Selling, general and administrative 25,744 40,933 Restructuring, long-lived assets impairment and related charges 12,712 3,372 ----------- ----------- Total operating expenses 233,684 189,371 ----------- ----------- Loss from operations (231,304) (186,732) Other income: Change in fair value of equity investments 1,130 (2,707) Interest income 17,527 21,931 Other (expense) income, net (893) 882 ----------- ----------- Total other income 17,764 20,106 ----------- ----------- Loss before (provision for) benefit from income taxes (213,540) (166,626) (Provision for) benefit from income taxes (177) 3,213 ----------- ----------- Net loss (213,717) (163,413) Net loss attributable to noncontrolling interest -- -- ----------- ----------- Net loss attributable to Vir $ (213,717) $ (163,413) =========== =========== Net loss per share attributable to Vir, basic and diluted $ (1.56) $ (1.22) =========== =========== Weighted-average shares outstanding, basic and diluted 136,653,753 134,289,620 =========== ===========